<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37259352</PMID><DateRevised><Year>2023</Year><Month>06</Month><Day>03</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">1424-8247</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Jan</Month><Day>29</Day></PubDate></JournalIssue><Title>Pharmaceuticals (Basel, Switzerland)</Title><ISOAbbreviation>Pharmaceuticals (Basel)</ISOAbbreviation></Journal><ArticleTitle>Direct-Acting Antivirals and Host-Targeting Approaches against Enterovirus B Infections: Recent Advances.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">203</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ph16020203</ELocationID><Abstract><AbstractText>Enterovirus B (EV-B)-related diseases, which can be life threatening in high-risk populations, have been recognized as a serious health problem, but their clinical treatment is largely supportive, and no selective antivirals are available on the market. As their clinical relevance has become more serious, efforts in the field of anti-EV-B inhibitors have greatly increased and many potential antivirals with very high selectivity indexes and promising in vitro activities have been discovered. The scope of this review encompasses recent advances in the discovery of new compounds with anti-viral activity against EV-B, as well as further progress in repurposing drugs to treat these infections. Current progress and future perspectives in drug discovery against EV-Bs are briefly discussed and existing gaps are spotlighted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tammaro</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-1748-2512</Identifier><AffiliationInfo><Affiliation>Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro, 5, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guida</LastName><ForeName>Michela</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-6487-1495</Identifier><AffiliationInfo><Affiliation>Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro, 5, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Appetecchia</LastName><ForeName>Federico</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0458-3349</Identifier><AffiliationInfo><Affiliation>Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro, 5, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biava</LastName><ForeName>Mariangela</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro, 5, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Consalvi</LastName><ForeName>Sara</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6562-7686</Identifier><AffiliationInfo><Affiliation>Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro, 5, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poce</LastName><ForeName>Giovanna</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7466-8861</Identifier><AffiliationInfo><Affiliation>Department of Chemistry and Technologies of Drug, Sapienza University of Rome, Piazzale A. Moro, 5, 00185 Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pharmaceuticals (Basel)</MedlineTA><NlmUniqueID>101238453</NlmUniqueID><ISSNLinking>1424-8247</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coxsackievirus</Keyword><Keyword MajorTopicYN="N">Enterovirus-B</Keyword><Keyword MajorTopicYN="N">Enterovirus-B inhibitors</Keyword><Keyword MajorTopicYN="N">antivirals</Keyword><Keyword MajorTopicYN="N">drug discovery</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>1</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>1</Day><Hour>1</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37259352</ArticleId><ArticleId IdType="pmc">PMC9966857</ArticleId><ArticleId IdType="doi">10.3390/ph16020203</ArticleId><ArticleId IdType="pii">ph16020203</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Anasir M.I., Zarif F., Poh C.L. Antivirals Blocking Entry of Enteroviruses and Therapeutic Potential. J. Biomed. Sci. 2021;28:10. doi: 10.1186/s12929-021-00708-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-021-00708-8</ArticleId><ArticleId IdType="pmc">PMC7811253</ArticleId><ArticleId IdType="pubmed">33451326</ArticleId></ArticleIdList></Reference><Reference><Citation>Zell R. Picornaviridae-the Ever-Growing Virus Family. Arch. Virol. 2018;163:299–317. doi: 10.1007/s00705-017-3614-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00705-017-3614-8</ArticleId><ArticleId IdType="pubmed">29058149</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggen J., Thibaut H.J., Strating J.R.P.M., van Kuppeveld F.J.M. The Life Cycle of Non-Polio Enteroviruses and How to Target It. Nat. Rev. Microbiol. 2018;16:368–381. doi: 10.1038/s41579-018-0005-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-018-0005-4</ArticleId><ArticleId IdType="pubmed">29626210</ArticleId></ArticleIdList></Reference><Reference><Citation>Nekoua M.P., Alidjinou E.K., Hober D. Persistent Coxsackievirus B Infection and Pathogenesis of Type 1 Diabetes Mellitus. Nat. Rev. Endocrinol. 2022;18:503–516. doi: 10.1038/s41574-022-00688-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-022-00688-1</ArticleId><ArticleId IdType="pmc">PMC9157043</ArticleId><ArticleId IdType="pubmed">35650334</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhazmi A., Nekoua M.P., Mercier A., Vergez I., Sane F., Alidjinou E.K., Hober D. Combating Coxsackievirus B Infections. Rev. Med. Virol. 2022;33:e2406. doi: 10.1002/rmv.2406.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2406</ArticleId><ArticleId IdType="pubmed">36371612</ArticleId></ArticleIdList></Reference><Reference><Citation>Laajala M., Reshamwala D., Marjomäki V. Therapeutic Targets for Enterovirus Infections. Expert. Opin. Ther. Targets. 2020;24:745–757. doi: 10.1080/14728222.2020.1784141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2020.1784141</ArticleId><ArticleId IdType="pubmed">32552314</ArticleId></ArticleIdList></Reference><Reference><Citation>Egorova A., Ekins S., Schmidtke M., Makarov V. Back to the Future: Advances in Development of Broad-Spectrum Capsid-Binding Inhibitors of Enteroviruses. Eur. J. Med. Chem. 2019;178:606–622. doi: 10.1016/j.ejmech.2019.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2019.06.008</ArticleId><ArticleId IdType="pmc">PMC8194503</ArticleId><ArticleId IdType="pubmed">31226653</ArticleId></ArticleIdList></Reference><Reference><Citation>Epstein S., Thakkar R., Fong K.T., Ng J., Bearden D.R., Mishra N., Thakur K.T., Riley C.S. Compassionate-Use Pocapavir and Immunoglobulin Therapy for Treatment of Rituximab-Associated Enterovirus Meningoencephalitis. J. Neurovirol. 2022;28:329–334. doi: 10.1007/s13365-021-01038-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13365-021-01038-z</ArticleId><ArticleId IdType="pubmed">34981437</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres-Torres S., Myers A.L., Klatte J.M., Rhoden E.E., Oberste M.S., Collett M.S., McCulloh R.J. First Use of Investigational Antiviral Drug Pocapavir (v-073) for Treating Neonatal Enteroviral Sepsis. Pediatr. Infect. Dis. J. 2015;34:52–54. doi: 10.1097/INF.0000000000000497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/INF.0000000000000497</ArticleId><ArticleId IdType="pubmed">25229269</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyllie T. P011 An Experimental Treatment for Enteroviral Sepsis. Arch. Dis. Child. 2019;104:e2. doi: 10.1136/archdischild-2019-nppc.21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/archdischild-2019-nppc.21</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer L., Lyoo H., van der Schaar H.M., Strating J.R., van Kuppeveld F.J. Direct-Acting Antivirals and Host-Targeting Strategies to Combat Enterovirus Infections. Curr. Opin. Virol. 2017;24:1–8. doi: 10.1016/j.coviro.2017.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.coviro.2017.03.009</ArticleId><ArticleId IdType="pmc">PMC7172203</ArticleId><ArticleId IdType="pubmed">28411509</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren P., Zheng Y., Wang W., Hong L., Delpeyroux F., Arenzana-Seisdedos F., Altmeyer R. Suramin Interacts with the Positively Charged Region Surrounding the 5-Fold Axis of the EV-A71 Capsid and Inhibits Multiple Enterovirus A. Sci. Rep. 2017;7:42902. doi: 10.1038/srep42902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep42902</ArticleId><ArticleId IdType="pmc">PMC5317167</ArticleId><ArticleId IdType="pubmed">28218309</ArticleId></ArticleIdList></Reference><Reference><Citation>Reshamwala D., Shroff S., Sheik Amamuddy O., Laquintana V., Denora N., Zacheo A., Lampinen V., Hytonen V.P., Tastan Bishop Ö., Krol S., et al. Polyphenols Epigallocatechin Gallate and Resveratrol, and Polyphenol-Functionalized Nanoparticles Prevent Enterovirus Infection through Clustering and Stabilization of the Viruses. Pharmaceutics. 2021;13:1182. doi: 10.3390/pharmaceutics13081182.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pharmaceutics13081182</ArticleId><ArticleId IdType="pmc">PMC8398301</ArticleId><ArticleId IdType="pubmed">34452144</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard A., Lacroix C., Cabiddu M.G., Neyts J., Leyssen P., Pompei R. Exploration of the Anti-Enterovirus Activity of a Series of Pleconaril/Pirodavir-like Compounds. Antivir. Chem. Chemother. 2015;24:56–61. doi: 10.1177/2040206615589035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2040206615589035</ArticleId><ArticleId IdType="pmc">PMC5890516</ArticleId><ArticleId IdType="pubmed">26071135</ArticleId></ArticleIdList></Reference><Reference><Citation>Egorova A., Kazakova E., Jahn B., Ekins S., Makarov V., Schmidtke M. Novel Pleconaril Derivatives: Influence of Substituents in the Isoxazole and Phenyl Rings on the Antiviral Activity against Enteroviruses. Eur. J. Med. Chem. 2020;188:112007. doi: 10.1016/j.ejmech.2019.112007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2019.112007</ArticleId><ArticleId IdType="pmc">PMC7002245</ArticleId><ArticleId IdType="pubmed">31881489</ArticleId></ArticleIdList></Reference><Reference><Citation>Makarov V.A., Braun H., Richter M., Riabova O.B., Kirchmair J., Kazakova E.S., Seidel N., Wutzler P., Schmidtke M. Pyrazolopyrimidines: Potent Inhibitors Targeting the Capsid of Rhino- and Enteroviruses. ChemMedChem. 2015;10:1629–1634. doi: 10.1002/cmdc.201500304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cmdc.201500304</ArticleId><ArticleId IdType="pmc">PMC4600222</ArticleId><ArticleId IdType="pubmed">26260222</ArticleId></ArticleIdList></Reference><Reference><Citation>Carta A., Sanna G., Briguglio I., Madeddu S., Vitale G., Piras S., Corona P., Peana A.T., Laurini E., Fermeglia M., et al. Quinoxaline Derivatives as New Inhibitors of Coxsackievirus B5. Eur. J. Med. Chem. 2018;145:559–569. doi: 10.1016/j.ejmech.2017.12.083.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2017.12.083</ArticleId><ArticleId IdType="pubmed">29339251</ArticleId></ArticleIdList></Reference><Reference><Citation>Madeddu S., Ibba R., Sanna G., Piras S., Riu F., Marongiu A., Ambrosino A., Caria P., Onnis V., Franci G., et al. Human Enterovirus B: Selective Inhibition by Quinoxaline Derivatives and Bioinformatic RNA-Motif Identification as New Targets. Pharmaceuticals. 2022;15:181. doi: 10.3390/ph15020181.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph15020181</ArticleId><ArticleId IdType="pmc">PMC8878107</ArticleId><ArticleId IdType="pubmed">35215294</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y., Abdelnabi R., Delang L., Froeyen M., Luyten W., Neyts J., Mirabelli C. New Class of Early-Stage Enterovirus Inhibitors with a Novel Mechanism of Action. Antivir. Res. 2017;147:67–74. doi: 10.1016/j.antiviral.2017.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.10.004</ArticleId><ArticleId IdType="pubmed">28993161</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelnabi R., Geraets J.A., Ma Y., Mirabelli C., Flatt J.W., Domanska A., Delang L., Jochmans D., Kumar T.A., Jayaprakash V., et al. A Novel Druggable Interprotomer Pocket in the Capsid of Rhino- and Enteroviruses. PLoS Biol. 2019;17:e3000281. doi: 10.1371/journal.pbio.3000281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3000281</ArticleId><ArticleId IdType="pmc">PMC6559632</ArticleId><ArticleId IdType="pubmed">31185007</ArticleId></ArticleIdList></Reference><Reference><Citation>Shetnev A.A., Volobueva A.S., Panova V.A., Zarubaev V.V., Baykov S.V. Design of 4-Substituted Sulfonamidobenzoic Acid Derivatives Targeting Coxsackievirus B3. Life. 2022;12:1832. doi: 10.3390/life12111832.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/life12111832</ArticleId><ArticleId IdType="pmc">PMC9694965</ArticleId><ArticleId IdType="pubmed">36362987</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayden F.G., Turner R.B., Gwaltney J.M., Chi-Burris K., Gersten M., Hsyu P., Patick A.K., Smith G.J., Zalman L.S. Phase II, Randomized, Double-Blind, Placebo-Controlled Studies of Ruprintrivir Nasal Spray 2-Percent Suspension for Prevention and Treatment of Experimentally Induced Rhinovirus Colds in Healthy Volunteers. Antimicrob. Agents Chemother. 2003;47:3907–3916. doi: 10.1128/AAC.47.12.3907-3916.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.47.12.3907-3916.2003</ArticleId><ArticleId IdType="pmc">PMC296196</ArticleId><ArticleId IdType="pubmed">14638501</ArticleId></ArticleIdList></Reference><Reference><Citation>Patick A.K., Brothers M.A., Maldonado F., Binford S., Maldonado O., Fuhrman S., Petersen A., Smith G.J., Zalman L.S., Burns-Naas L.A., et al. In Vitro Antiviral Activity and Single-Dose Pharmacokinetics in Humans of a Novel, Orally Bioavailable Inhibitor of Human Rhinovirus 3C Protease. Antimicrob. Agents Chemother. 2005;49:2267–2275. doi: 10.1128/AAC.49.6.2267-2275.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.49.6.2267-2275.2005</ArticleId><ArticleId IdType="pmc">PMC1140523</ArticleId><ArticleId IdType="pubmed">15917520</ArticleId></ArticleIdList></Reference><Reference><Citation>Ianevski A., Zusinaite E., Tenson T., Oksenych V., Wang W., Afset J.E., Bjørås M., Kainov D.E. Novel Synergistic Anti-Enteroviral Drug Combinations. Viruses. 2022;14:1866. doi: 10.3390/v14091866.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14091866</ArticleId><ArticleId IdType="pmc">PMC9505890</ArticleId><ArticleId IdType="pubmed">36146673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kankam M.K., Burns J.M., Collett M.S., Corrado M.L., Hincks J.R. A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers. Antimicrob. Agents Chemother. 2021;65:e0102921. doi: 10.1128/AAC.01029-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.01029-21</ArticleId><ArticleId IdType="pmc">PMC8448163</ArticleId><ArticleId IdType="pubmed">34370575</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhoden E., Liu H.-M., Wang-Chern S.-W., Oberste M.S. Anti-Poliovirus Activity of Protease Inhibitor AG-7404, and Assessment of in Vitro Activity in Combination with Antiviral Capsid Inhibitor Compounds. Antivir. Res. 2013;98:186–191. doi: 10.1016/j.antiviral.2013.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.03.003</ArticleId><ArticleId IdType="pubmed">23499651</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Linden L., Ulferts R., Nabuurs S.B., Kusov Y., Liu H., George S., Lacroix C., Goris N., Lefebvre D., Lanke K.H.W., et al. Application of a Cell-Based Protease Assay for Testing Inhibitors of Picornavirus 3C Proteases. Antivir. Res. 2014;103:17–24. doi: 10.1016/j.antiviral.2013.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2013.12.012</ArticleId><ArticleId IdType="pmc">PMC7113757</ArticleId><ArticleId IdType="pubmed">24393668</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Y.W., Ang M.J.Y., Lau Q.Y., Poulsen A., Ng F.M., Then S.W., Peng J., Hill J., Hong W.J., Chia C.S.B., et al. Antiviral Activities of Peptide-Based Covalent Inhibitors of the Enterovirus 71 3C Protease. Sci. Rep. 2016;6:33663. doi: 10.1038/srep33663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep33663</ArticleId><ArticleId IdType="pmc">PMC5028882</ArticleId><ArticleId IdType="pubmed">27645381</ArticleId></ArticleIdList></Reference><Reference><Citation>Marjomäki V., Kalander K., Hellman M., Permi P. Enteroviruses and Coronaviruses: Similarities and Therapeutic Targets. Expert. Opin. Ther. Targets. 2021;25:479–489. doi: 10.1080/14728222.2021.1952985.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14728222.2021.1952985</ArticleId><ArticleId IdType="pmc">PMC8330013</ArticleId><ArticleId IdType="pubmed">34253126</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Lin D., Kusov Y., Nian Y., Ma Q., Wang J., von Brunn A., Leyssen P., Lanko K., Neyts J., et al. α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment. J. Med. Chem. 2020;63:4562–4578. doi: 10.1021/acs.jmedchem.9b01828.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.9b01828</ArticleId><ArticleId IdType="pubmed">32045235</ArticleId></ArticleIdList></Reference><Reference><Citation>Dai W., Jochmans D., Xie H., Yang H., Li J., Su H., Chang D., Wang J., Peng J., Zhu L., et al. Design, Synthesis, and Biological Evaluation of Peptidomimetic Aldehydes as Broad-Spectrum Inhibitors against Enterovirus and SARS-CoV-2. J. Med. Chem. 2022;65:2794–2808. doi: 10.1021/acs.jmedchem.0c02258.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.0c02258</ArticleId><ArticleId IdType="pubmed">33872498</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulz R., Atef A., Becker D., Gottschalk F., Tauber C., Wagner S., Arkona C., Abdel-Hafez A.A., Farag H.H., Rademann J., et al. Phenylthiomethyl Ketone-Based Fragments Show Selective and Irreversible Inhibition of Enteroviral 3C Proteases. J. Med. Chem. 2018;61:1218–1230. doi: 10.1021/acs.jmedchem.7b01440.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.7b01440</ArticleId><ArticleId IdType="pubmed">29328649</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim B.-K., Ko H., Jeon E.-S., Ju E.-S., Jeong L.S., Kim Y.-C. 2,3,4-Trihydroxybenzyl-Hydrazide Analogues as Novel Potent Coxsackievirus B3 3C Protease Inhibitors. Eur. J. Med. Chem. 2016;120:202–216. doi: 10.1016/j.ejmech.2016.03.085.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2016.03.085</ArticleId><ArticleId IdType="pubmed">27191615</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer L., Manganaro R., Zonsics B., Strating J.R.P.M., El Kazzi P., Lorenzo Lopez M., Ulferts R., van Hoey C., Maté M.J., Langer T., et al. Fluoxetine Inhibits Enterovirus Replication by Targeting the Viral 2C Protein in a Stereospecific Manner. ACS Infect. Dis. 2019;5:1609–1623. doi: 10.1021/acsinfecdis.9b00179.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.9b00179</ArticleId><ArticleId IdType="pmc">PMC6747591</ArticleId><ArticleId IdType="pubmed">31305993</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurdiss D.L., El Kazzi P., Bauer L., Papageorgiou N., Ferron F.P., Donselaar T., van Vliet A.L.W., Shamorkina T.M., Snijder J., Canard B., et al. Fluoxetine Targets an Allosteric Site in the Enterovirus 2C AAA+ ATPase and Stabilizes a Ring-Shaped Hexameric Complex. Sci. Adv. 2022;8:eabj7615. doi: 10.1126/sciadv.abj7615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abj7615</ArticleId><ArticleId IdType="pmc">PMC8730599</ArticleId><ArticleId IdType="pubmed">34985963</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma A.M., Heggermont W., Lanke K., Coutard B., Bergmann M., Monforte A.-M., Canard B., De Clercq E., Chimirri A., Pürstinger G., et al. The Thiazolobenzimidazole TBZE-029 Inhibits Enterovirus Replication by Targeting a Short Region Immediately Downstream from Motif C in the Nonstructural Protein 2C. J. Virol. 2008;82:4720–4730. doi: 10.1128/JVI.01338-07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01338-07</ArticleId><ArticleId IdType="pmc">PMC2346740</ArticleId><ArticleId IdType="pubmed">18337578</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Zhi C., Li H., Huang D., Fan Q., Cui J., Liang C. Umifenovir Effectively Inhibits IL-10 Dependent Persistent Coxsackie B4 Virus Infection. Antivir. Res. 2017;141:165–173. doi: 10.1016/j.antiviral.2017.02.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.02.018</ArticleId><ArticleId IdType="pubmed">28263801</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Yan K., Wang Y., Cai J., Wei L., Li S., Xu W., Li M. Lithium Chloride Confers Protection against Viral Myocarditis via Suppression of Coxsackievirus B3 Virus Replication. Microb. Pathog. 2020;144:104169. doi: 10.1016/j.micpath.2020.104169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2020.104169</ArticleId><ArticleId IdType="pmc">PMC7102605</ArticleId><ArticleId IdType="pubmed">32205210</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Zhao S., Chen Y., Wang Y., Wang T., Wo X., Dong Y., Zhang J., Xu W., Qu C., et al. N-Acetyl Cysteine Effectively Alleviates Coxsackievirus B-Induced Myocarditis through Suppressing Viral Replication and Inflammatory Response. Antivir. Res. 2020;179:104699. doi: 10.1016/j.antiviral.2019.104699.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2019.104699</ArticleId><ArticleId IdType="pubmed">31883926</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S., Wang H.-Q., Guo T.-T., Li Y.-H. Luteolin Inhibits CVB3 Replication through Inhibiting Inflammation. J. Asian Nat. Prod. Res. 2020;22:762–773. doi: 10.1080/10286020.2019.1642329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10286020.2019.1642329</ArticleId><ArticleId IdType="pubmed">31321999</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Liu G., Jia J., Zhong J., Yan R., Lin X., Zheng K., Zhu Q. In-Vitro Antiviral Activity of Doxepin Hydrochloride against Group B Coxsackievirus. Virus Res. 2022;317:198816. doi: 10.1016/j.virusres.2022.198816.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virusres.2022.198816</ArticleId><ArticleId IdType="pubmed">35598772</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo J., Quinn K.K., Kye S., Cooper P., Damoiseaux R., Krogstad P. Fluoxetine Is a Potent Inhibitor of Coxsackie virus Replication. Antimicrob. Agents Chemother. 2012;56:4838–4844. doi: 10.1128/AAC.00983-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00983-12</ArticleId><ArticleId IdType="pmc">PMC3421851</ArticleId><ArticleId IdType="pubmed">22751539</ArticleId></ArticleIdList></Reference><Reference><Citation>Manganaro R., Zonsics B., Bauer L., Lorenzo Lopez M., Donselaar T., Zwaagstra M., Saporito F., Ferla S., Strating J.R.P.M., Coutard B., et al. Synthesis and Antiviral Effect of Novel Fluoxetine Analogues as Enterovirus 2C Inhibitors. Antivir. Res. 2020;178:104781. doi: 10.1016/j.antiviral.2020.104781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104781</ArticleId><ArticleId IdType="pubmed">32234539</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulferts R., de Boer S.M., van der Linden L., Bauer L., Lyoo H.R., Maté M.J., Lichière J., Canard B., Lelieveld D., Omta W., et al. Screening of a Library of FDA-Approved Drugs Identifies Several Enterovirus Replication Inhibitors That Target Viral Protein 2C. Antimicrob. Agents Chemother. 2016;60:2627–2638. doi: 10.1128/AAC.02182-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02182-15</ArticleId><ArticleId IdType="pmc">PMC4862474</ArticleId><ArticleId IdType="pubmed">26856848</ArticleId></ArticleIdList></Reference><Reference><Citation>Musharrafieh R., Kitamura N., Hu Y., Wang J. Development of Broad-Spectrum Enterovirus Antivirals Based on Quinoline Scaffold. Bioorg. Chem. 2020;101:103981. doi: 10.1016/j.bioorg.2020.103981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioorg.2020.103981</ArticleId><ArticleId IdType="pmc">PMC7390679</ArticleId><ArticleId IdType="pubmed">32559580</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo J., Kye S., Quinn K.K., Cooper P., Damoiseaux R., Krogstad P. Discovery of Structurally Diverse Small-Molecule Compounds with Broad Antiviral Activity against Enteroviruses. Antimicrob. Agents Chemother. 2015;60:1615–1626. doi: 10.1128/AAC.02646-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.02646-15</ArticleId><ArticleId IdType="pmc">PMC4775951</ArticleId><ArticleId IdType="pubmed">26711750</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer L., Manganaro R., Zonsics B., Hurdiss D.L., Zwaagstra M., Donselaar T., Welter N.G.E., van Kleef R.G.D.M., Lopez M.L., Bevilacqua F., et al. Rational Design of Highly Potent Broad-Spectrum Enterovirus Inhibitors Targeting the Nonstructural Protein 2C. PLoS Biol. 2020;18:e3000904. doi: 10.1371/journal.pbio.3000904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.3000904</ArticleId><ArticleId IdType="pmc">PMC7673538</ArticleId><ArticleId IdType="pubmed">33156822</ArticleId></ArticleIdList></Reference><Reference><Citation>Xing Y., Zuo J., Krogstad P., Jung M.E. Synthesis and Structure-Activity Relationship (SAR) Studies of Novel Pyrazolopyridine Derivatives as Inhibitors of Enterovirus Replication. J. Med. Chem. 2018;61:1688–1703. doi: 10.1021/acs.jmedchem.7b01863.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.7b01863</ArticleId><ArticleId IdType="pubmed">29346733</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu Y., Kitamura N., Musharrafieh R., Wang J. Discovery of Potent and Broad-Spectrum Pyrazolopyridine-Containing Antivirals against Enteroviruses D68, A71, and Coxsackievirus B3 by Targeting the Viral 2C Protein. J. Med. Chem. 2021;64:8755–8774. doi: 10.1021/acs.jmedchem.1c00758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.1c00758</ArticleId><ArticleId IdType="pmc">PMC9179928</ArticleId><ArticleId IdType="pubmed">34085827</ArticleId></ArticleIdList></Reference><Reference><Citation>Belvisi L., D’Andrea L.D., Jiménez M.A. Editorial: Peptides Targeting Protein-Protein Interactions: Methods and Applications. Front. Mol. Biosci. 2021;8:780106. doi: 10.3389/fmolb.2021.780106.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.780106</ArticleId><ArticleId IdType="pmc">PMC8552004</ArticleId><ArticleId IdType="pubmed">34722638</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y., Wang C., Wang C., Yang R., Bai P., Zhang X.-Y., Kong J., Yin L., Qiu Y., Zhou X. Antiviral Peptides Targeting the Helicase Activity of Enterovirus Nonstructural Protein 2C. J. Virol. 2021;95:e02324-20. doi: 10.1128/JVI.02324-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02324-20</ArticleId><ArticleId IdType="pmc">PMC8315976</ArticleId><ArticleId IdType="pubmed">33789997</ArticleId></ArticleIdList></Reference><Reference><Citation>Strating J.R.P.M., van der Linden L., Albulescu L., Bigay J., Arita M., Delang L., Leyssen P., van der Schaar H.M., Lanke K.H.W., Thibaut H.J., et al. Itraconazole Inhibits Enterovirus Replication by Targeting the Oxysterol-Binding Protein. Cell. Rep. 2015;10:600–615. doi: 10.1016/j.celrep.2014.12.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2014.12.054</ArticleId><ArticleId IdType="pmc">PMC4383725</ArticleId><ArticleId IdType="pubmed">25640182</ArticleId></ArticleIdList></Reference><Reference><Citation>Rattanakomol P., Srimanote P., Tongtawe P., Khantisitthiporn O., Supasorn O., Thanongsaksrikul J. Host Neuronal PRSS3 Interacts with Enterovirus A71 3A Protein and Its Role in Viral Replication. Sci. Rep. 2022;12:12846. doi: 10.1038/s41598-022-17272-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-17272-2</ArticleId><ArticleId IdType="pmc">PMC9328647</ArticleId><ArticleId IdType="pubmed">35896602</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz B.A., Vance L.M. The Antiviral Compound Enviroxime Targets the 3A Coding Region of Rhinovirus and Poliovirus. J. Virol. 1995;69:4189–4197. doi: 10.1128/jvi.69.7.4189-4197.1995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.69.7.4189-4197.1995</ArticleId><ArticleId IdType="pmc">PMC189156</ArticleId><ArticleId IdType="pubmed">7769678</ArticleId></ArticleIdList></Reference><Reference><Citation>Phillpotts R.J., Jones R.W., Delong D.C., Reed S.E., Wallace J., Tyrrell D.A. The Activity of Enviroxime against Rhinovirus Infection in Man. Lancet. 1981;1:1342–1344. doi: 10.1016/S0140-6736(81)92520-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(81)92520-4</ArticleId><ArticleId IdType="pubmed">6113314</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma A.M., Thibaut H.J., van der Linden L., Lanke K., Heggermont W., Ireland S., Andrews R., Arimilli M., Al-Tel T.H., De Clercq E., et al. Mutations in the Nonstructural Protein 3A Confer Resistance to the Novel Enterovirus Replication Inhibitor TTP-8307. Antimicrob. Agents Chemother. 2009;53:1850–1857. doi: 10.1128/AAC.00934-08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.00934-08</ArticleId><ArticleId IdType="pmc">PMC2681499</ArticleId><ArticleId IdType="pubmed">19237651</ArticleId></ArticleIdList></Reference><Reference><Citation>Albulescu L., Bigay J., Biswas B., Weber-Boyvat M., Dorobantu C.M., Delang L., van der Schaar H.M., Jung Y.-S., Neyts J., Olkkonen V.M., et al. Uncovering Oxysterol-Binding Protein (OSBP) as a Target of the Anti-Enteroviral Compound TTP-8307. Antivir. Res. 2017;140:37–44. doi: 10.1016/j.antiviral.2017.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2017.01.008</ArticleId><ArticleId IdType="pubmed">28088354</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao Q., Yuan S., Zhang C., Wang Y., Wang Y., He G., Zhang S., Altmeyer R., Zou G. Discovery of Itraconazole with Broad-Spectrum in Vitro Antienterovirus Activity That Targets Nonstructural Protein 3A. Antimicrob. Agents Chemother. 2015;59:2654–2665. doi: 10.1128/AAC.05108-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/AAC.05108-14</ArticleId><ArticleId IdType="pmc">PMC4394834</ArticleId><ArticleId IdType="pubmed">25691649</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Linden L., Wolthers K.C., van Kuppeveld F.J.M. Replication and Inhibitors of Enteroviruses and Parechoviruses. Viruses. 2015;7:4529–4562. doi: 10.3390/v7082832.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v7082832</ArticleId><ArticleId IdType="pmc">PMC4576193</ArticleId><ArticleId IdType="pubmed">26266417</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang H., Kim C., Kim D., Song J.-H., Choi M., Choi K., Kang M., Lee K., Kim H.S., Shin J.S., et al. Synergistic Antiviral Activity of Gemcitabine and Ribavirin against Enteroviruses. Antivir. Res. 2015;124:1–10. doi: 10.1016/j.antiviral.2015.10.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2015.10.011</ArticleId><ArticleId IdType="pubmed">26526589</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K., Kim D.-E., Jang K.-S., Kim S.-J., Cho S., Kim C. Gemcitabine, a Broad-Spectrum Antiviral Drug, Suppresses Enterovirus Infections through Innate Immunity Induced by the Inhibition of Pyrimidine Biosynthesis and Nucleotide Depletion. Oncotarget. 2017;8:115315–115325. doi: 10.18632/oncotarget.23258.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.23258</ArticleId><ArticleId IdType="pmc">PMC5777774</ArticleId><ArticleId IdType="pubmed">29383162</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Linden L., Vives-Adrián L., Selisko B., Ferrer-Orta C., Liu X., Lanke K., Ulferts R., De Palma A.M., Tanchis F., Goris N., et al. The RNA Template Channel of the RNA-Dependent RNA Polymerase as a Target for Development of Antiviral Therapy of Multiple Genera within a Virus Family. PLoS Pathog. 2015;11:e1004733. doi: 10.1371/journal.ppat.1004733.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004733</ArticleId><ArticleId IdType="pmc">PMC4370873</ArticleId><ArticleId IdType="pubmed">25799064</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind K., Svedin E., Domsgen E., Kapell S., Laitinen O.H., Moll M., Flodström-Tullberg M. Coxsackievirus Counters the Host Innate Immune Response by Blocking Type III Interferon Expression. J. Gen. Virol. 2016;97:1368–1380. doi: 10.1099/jgv.0.000443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.000443</ArticleId><ArticleId IdType="pubmed">26935471</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung N.N., Lai K.K., Dai J., Kok K.H., Chen H., Chan K.-H., Yuen K.-Y., Kao R.Y.T. Broad-Spectrum Inhibition of Common Respiratory RNA Viruses by a Pyrimidine Synthesis Inhibitor with Involvement of the Host Antiviral Response. J. Gen. Virol. 2017;98:946–954. doi: 10.1099/jgv.0.000758.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.000758</ArticleId><ArticleId IdType="pubmed">28555543</ArticleId></ArticleIdList></Reference><Reference><Citation>Huan C., Qu X., Li Z. Host Restrictive Factors Are the Emerging Storm Troopers Against Enterovirus: A Mini-Review. Front. Immunol. 2022;13:910780. doi: 10.3389/fimmu.2022.910780.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.910780</ArticleId><ArticleId IdType="pmc">PMC9114347</ArticleId><ArticleId IdType="pubmed">35603180</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji X., Li Z. Medicinal Chemistry Strategies toward Host Targeting Antiviral Agents. Med. Res. Rev. 2020;40:1519–1557. doi: 10.1002/med.21664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.21664</ArticleId><ArticleId IdType="pmc">PMC7228277</ArticleId><ArticleId IdType="pubmed">32060956</ArticleId></ArticleIdList></Reference><Reference><Citation>Owino C.O., Chu J.J.H. Recent Advances on the Role of Host Factors during Non-Poliovirus Enteroviral Infections. J. Biomed. Sci. 2019;26:47. doi: 10.1186/s12929-019-0540-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0540-y</ArticleId><ArticleId IdType="pmc">PMC6582496</ArticleId><ArticleId IdType="pubmed">31215493</ArticleId></ArticleIdList></Reference><Reference><Citation>Peischard S., Ho H.T., Theiss C., Strutz-Seebohm N., Seebohm G. A Kidnapping Story: How Coxsackievirus B3 and Its Host Cell Interact. Cell Physiol. Biochem. 2019;53:121–140. doi: 10.33594/000000125.</Citation><ArticleIdList><ArticleId IdType="doi">10.33594/000000125</ArticleId><ArticleId IdType="pubmed">31230428</ArticleId></ArticleIdList></Reference><Reference><Citation>Duyvesteyn H.M.E., Ren J., Walter T.S., Fry E.E., Stuart D.I. Glutathione Facilitates Enterovirus Assembly by Binding at a Druggable Pocket. Commun. Biol. 2020;3:9. doi: 10.1038/s42003-019-0722-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-019-0722-x</ArticleId><ArticleId IdType="pmc">PMC6941975</ArticleId><ArticleId IdType="pubmed">31909201</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma H.-C., Liu Y., Wang C., Strauss M., Rehage N., Chen Y.-H., Altan-Bonnet N., Hogle J., Wimmer E., Mueller S., et al. An Interaction between Glutathione and the Capsid Is Required for the Morphogenesis of C-Cluster Enteroviruses. PLoS Pathog. 2014;10:e1004052. doi: 10.1371/journal.ppat.1004052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004052</ArticleId><ArticleId IdType="pmc">PMC3983063</ArticleId><ArticleId IdType="pubmed">24722315</ArticleId></ArticleIdList></Reference><Reference><Citation>Moghimi S., Viktorova E., Zimina A., Szul T., Sztul E., Belov G.A. Enterovirus Infection Induces Massive Recruitment of All Isoforms of Small Cellular Arf GTPases to the Replication Organelles. J. Virol. 2020;95:e01629-20. doi: 10.1128/JVI.01629-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01629-20</ArticleId><ArticleId IdType="pmc">PMC7944459</ArticleId><ArticleId IdType="pubmed">33087467</ArticleId></ArticleIdList></Reference><Reference><Citation>Thibaut H.J., van der Linden L., Jiang P., Thys B., Canela M.-D., Aguado L., Rombaut B., Wimmer E., Paul A., Pérez-Pérez M.-J., et al. Binding of Glutathione to Enterovirus Capsids Is Essential for Virion Morphogenesis. PLoS Pathog. 2014;10:e1004039. doi: 10.1371/journal.ppat.1004039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1004039</ArticleId><ArticleId IdType="pmc">PMC3983060</ArticleId><ArticleId IdType="pubmed">24722756</ArticleId></ArticleIdList></Reference><Reference><Citation>Seizer P., Klingel K., Sauter M., Westermann D., Ochmann C., Schönberger T., Schleicher R., Stellos K., Schmidt E.-M., Borst O., et al. Cyclophilin A Affects Inflammation, Virus Elimination and Myocardial Fibrosis in Coxsackievirus B3-Induced Myocarditis. J. Mol Cell Cardiol. 2012;53:6–14. doi: 10.1016/j.yjmcc.2012.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2012.03.004</ArticleId><ArticleId IdType="pubmed">22446162</ArticleId></ArticleIdList></Reference><Reference><Citation>Geller R., Vignuzzi M., Andino R., Frydman J. Evolutionary Constraints on Chaperone-Mediated Folding Provide an Antiviral Approach Refractory to Development of Drug Resistance. Genes Dev. 2007;21:195–205. doi: 10.1101/gad.1505307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1505307</ArticleId><ArticleId IdType="pmc">PMC1770902</ArticleId><ArticleId IdType="pubmed">17234885</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanke K.H.W., van der Schaar H.M., Belov G.A., Feng Q., Duijsings D., Jackson C.L., Ehrenfeld E., van Kuppeveld F.J.M. GBF1, a Guanine Nucleotide Exchange Factor for Arf, Is Crucial for Coxsackievirus B3 RNA Replication. J. Virol. 2009;83:11940–11949. doi: 10.1128/JVI.01244-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01244-09</ArticleId><ArticleId IdType="pmc">PMC2772713</ArticleId><ArticleId IdType="pubmed">19740986</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Linden L., van der Schaar H.M., Lanke K.H.W., Neyts J., van Kuppeveld F.J.M. Differential Effects of the Putative GBF1 Inhibitors Golgicide A and AG1478 on Enterovirus Replication. J. Virol. 2010;84:7535–7542. doi: 10.1128/JVI.02684-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02684-09</ArticleId><ArticleId IdType="pmc">PMC2897619</ArticleId><ArticleId IdType="pubmed">20504936</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferlin J., Farhat R., Belouzard S., Cocquerel L., Bertin A., Hober D., Dubuisson J., Rouillé Y. Investigation of the Role of GBF1 in the Replication of Positive-Sense Single-Stranded RNA Viruses. J. Gen. Virol. 2018;99:1086–1096. doi: 10.1099/jgv.0.001099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001099</ArticleId><ArticleId IdType="pubmed">29923822</ArticleId></ArticleIdList></Reference><Reference><Citation>Martínez J.L., Arias C.F. Role of the Guanine Nucleotide Exchange Factor GBF1 in the Replication of RNA Viruses. Viruses. 2020;12:682. doi: 10.3390/v12060682.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12060682</ArticleId><ArticleId IdType="pmc">PMC7354614</ArticleId><ArticleId IdType="pubmed">32599855</ArticleId></ArticleIdList></Reference><Reference><Citation>Viktorova E.G., Nchoutmboube J.A., Ford-Siltz L.A., Iverson E., Belov G.A. Phospholipid Synthesis Fueled by Lipid Droplets Drives the Structural Development of Poliovirus Replication Organelles. PLoS Pathog. 2018;14:e1007280. doi: 10.1371/journal.ppat.1007280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1007280</ArticleId><ArticleId IdType="pmc">PMC6128640</ArticleId><ArticleId IdType="pubmed">30148882</ArticleId></ArticleIdList></Reference><Reference><Citation>Quaranta P., Lottini G., Chesi G., Contrafatto F., Russotto R., Macera L., Lai M., Spezia P.G., Brai A., Botta M., et al. DDX3 Inhibitors Show Antiviral Activity against Positive-Sense Single-Stranded RNA Viruses but Not against Negative-Sense Single-Stranded RNA Viruses: The Coxsackie B Model. Antivir. Res. 2020;178:104750. doi: 10.1016/j.antiviral.2020.104750.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2020.104750</ArticleId><ArticleId IdType="pubmed">32205137</ArticleId></ArticleIdList></Reference><Reference><Citation>Laufman O., Perrino J., Andino R. Viral Generated Inter-Organelle Contacts Redirect Lipid Flux for Genome Replication. Cell. 2019;178:275–289. doi: 10.1016/j.cell.2019.05.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2019.05.030</ArticleId><ArticleId IdType="pmc">PMC7077330</ArticleId><ArticleId IdType="pubmed">31204099</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Wang M., Cheng A., Wen X., Ou X., Mao S., Gao Q., Sun D., Jia R., Yang Q., et al. Enterovirus Replication Organelles and Inhibitors of Their Formation. Front. Microbiol. 2020;11:1817. doi: 10.3389/fmicb.2020.01817.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.01817</ArticleId><ArticleId IdType="pmc">PMC7468505</ArticleId><ArticleId IdType="pubmed">32973693</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Schaar H.M., van der Linden L., Lanke K.H.W., Strating J.R.P.M., Pürstinger G., de Vries E., de Haan C.A.M., Neyts J., van Kuppeveld F.J.M. Coxsackievirus Mutants That Can Bypass Host Factor PI4KIIIβ and the Need for High Levels of PI4P Lipids for Replication. Cell Res. 2012;22:1576–1592. doi: 10.1038/cr.2012.129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cr.2012.129</ArticleId><ArticleId IdType="pmc">PMC3494396</ArticleId><ArticleId IdType="pubmed">22945356</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Kojima H., Nagano T., Okabe T., Wakita T., Shimizu H. Phosphatidylinositol 4-Kinase III Beta Is a Target of Enviroxime-like Compounds for Antipoliovirus Activity. J. Virol. 2011;85:2364–2372. doi: 10.1128/JVI.02249-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02249-10</ArticleId><ArticleId IdType="pmc">PMC3067798</ArticleId><ArticleId IdType="pubmed">21177810</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Philipov S., Galabov A.S. Phosphatidylinositol 4-Kinase III Beta Is the Target of Oxoglaucine and Pachypodol (Ro 09-0179) for Their Anti-Poliovirus Activities, and Is Located at Upstream of the Target Step of Brefeldin A. Microbiol. Immunol. 2015;59:338–347. doi: 10.1111/1348-0421.12261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1348-0421.12261</ArticleId><ArticleId IdType="pubmed">25891300</ArticleId></ArticleIdList></Reference><Reference><Citation>Šála M., Kögler M., Plačková P., Mejdrová I., Hřebabecký H., Procházková E., Strunin D., Lee G., Birkus G., Weber J., et al. Purine Analogs as Phosphatidylinositol 4-Kinase IIIβ Inhibitors. Bioorg. Med. Chem Lett. 2016;26:2706–2712. doi: 10.1016/j.bmcl.2016.04.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2016.04.002</ArticleId><ArticleId IdType="pmc">PMC7127540</ArticleId><ArticleId IdType="pubmed">27090557</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejdrová I., Chalupská D., Plačková P., Müller C., Šála M., Klíma M., Baumlová A., Hřebabecký H., Procházková E., Dejmek M., et al. Rational Design of Novel Highly Potent and Selective Phosphatidylinositol 4-Kinase IIIβ (PI4KB) Inhibitors as Broad-Spectrum Antiviral Agents and Tools for Chemical Biology. J. Med. Chem. 2017;60:100–118. doi: 10.1021/acs.jmedchem.6b01465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.jmedchem.6b01465</ArticleId><ArticleId IdType="pubmed">28004945</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Dobrikov G., Pürstinger G., Galabov A.S. Allosteric Regulation of Phosphatidylinositol 4-Kinase III Beta by an Antipicornavirus Compound MDL-860. ACS Infect. Dis. 2017;3:585–594. doi: 10.1021/acsinfecdis.7b00053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acsinfecdis.7b00053</ArticleId><ArticleId IdType="pubmed">28605587</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobrikov G.M., Slavchev I., Nikolova I., Stoyanova A., Nikolova N., Mukova L., Nikolova R., Shivachev B., Galabov A.S. Synthesis and Anti-Enterovirus Activity of New Analogues of MDL-860. Bioorg. Med. Chem. Lett. 2017;27:4540–4543. doi: 10.1016/j.bmcl.2017.08.056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmcl.2017.08.056</ArticleId><ArticleId IdType="pubmed">28870395</ArticleId></ArticleIdList></Reference><Reference><Citation>Nikolova I., Slavchev I., Ravutsov M., Dangalov M., Nikolova Y., Zagranyarska I., Stoyanova A., Nikolova N., Mukova L., Grozdanov P., et al. Anti-Enteroviral Activity of New MDL-860 Analogues: Synthesis, in Vitro/in Vivo Studies and QSAR Analysis. Bioorg. Chem. 2019;85:487–497. doi: 10.1016/j.bioorg.2019.02.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bioorg.2019.02.020</ArticleId><ArticleId IdType="pubmed">30782563</ArticleId></ArticleIdList></Reference><Reference><Citation>Albulescu L., Strating J.R.P.M., Thibaut H.J., van der Linden L., Shair M.D., Neyts J., van Kuppeveld F.J.M. Broad-Range Inhibition of Enterovirus Replication by OSW-1, a Natural Compound Targeting OSBP. Antivir. Res. 2015;117:110–114. doi: 10.1016/j.antiviral.2015.02.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2015.02.013</ArticleId><ArticleId IdType="pubmed">25752737</ArticleId></ArticleIdList></Reference><Reference><Citation>Arita M., Kojima H., Nagano T., Okabe T., Wakita T., Shimizu H. Oxysterol-Binding Protein Family I Is the Target of Minor Enviroxime-like Compounds. J. Virol. 2013;87:4252–4260. doi: 10.1128/JVI.03546-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.03546-12</ArticleId><ArticleId IdType="pmc">PMC3624399</ArticleId><ArticleId IdType="pubmed">23365445</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts B.L., Severance Z.C., Bensen R.C., Le-McClain A.T., Malinky C.A., Mettenbrink E.M., Nuñez J.I., Reddig W.J., Blewett E.L., Burgett A.W.G. Differing Activities of Oxysterol-Binding Protein (OSBP) Targeting Anti-Viral Compounds. Antivir. Res. 2019;170:104548. doi: 10.1016/j.antiviral.2019.104548.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2019.104548</ArticleId><ArticleId IdType="pmc">PMC10786240</ArticleId><ArticleId IdType="pubmed">31271764</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts B.L., Severance Z.C., Bensen R.C., Le A.T., Kothapalli N.R., Nuñez J.I., Ma H., Wu S., Standke S.J., Yang Z., et al. Transient Compound Treatment Induces a Multigenerational Reduction of Oxysterol-Binding Protein (OSBP) Levels and Prophylactic Antiviral Activity. ACS Chem. Biol. 2019;14:276–287. doi: 10.1021/acschembio.8b00984.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschembio.8b00984</ArticleId><ArticleId IdType="pmc">PMC6379863</ArticleId><ArticleId IdType="pubmed">30576108</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J.-S., Choi H.-J., Song J.-H., Ko H.-J., Yoon K., Seong J.-M. Antiviral Activity of Itraconazole against Echovirus 30 Infection In Vitro. Osong. Public Health Res. Perspect. 2017;8:318–324. doi: 10.24171/j.phrp.2017.8.5.05.</Citation><ArticleIdList><ArticleId IdType="doi">10.24171/j.phrp.2017.8.5.05</ArticleId><ArticleId IdType="pmc">PMC5678193</ArticleId><ArticleId IdType="pubmed">29164043</ArticleId></ArticleIdList></Reference><Reference><Citation>Policastro L.R., Dolci I., Godoy A.S., Silva Júnior J.V.J., Ruiz U.E.A., Santos I.A., Jardim A.C.G., Samby K., Burrows J.N., Wells T.N.C., et al. The Antifungal Itraconazole Is a Potent Inhibitor of Chikungunya Virus Replication. Viruses. 2022;14:1351. doi: 10.3390/v14071351.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14071351</ArticleId><ArticleId IdType="pmc">PMC9317443</ArticleId><ArticleId IdType="pubmed">35891332</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Damme E., De Meyer S., Bojkova D., Ciesek S., Cinatl J., De Jonghe S., Jochmans D., Leyssen P., Buyck C., Neyts J., et al. In Vitro Activity of Itraconazole against SARS-CoV-2. J. Med. Virol. 2021;93:4454–4460. doi: 10.1002/jmv.26917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26917</ArticleId><ArticleId IdType="pmc">PMC8014624</ArticleId><ArticleId IdType="pubmed">33666253</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer L., Ferla S., Head S.A., Bhat S., Pasunooti K.K., Shi W.Q., Albulescu L., Liu J.O., Brancale A., van Kuppeveld F.J.M., et al. Structure-Activity Relationship Study of Itraconazole, a Broad-Range Inhibitor of Picornavirus Replication That Targets Oxysterol-Binding Protein (OSBP) Antivir. Res. 2018;156:55–63. doi: 10.1016/j.antiviral.2018.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.antiviral.2018.05.010</ArticleId><ArticleId IdType="pubmed">29807040</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J., Hu Y., Zheng M. Enterovirus A71 Antivirals: Past, Present, and Future. Acta Pharm. Sin. B. 2022;12:1542–1566. doi: 10.1016/j.apsb.2021.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.apsb.2021.08.017</ArticleId><ArticleId IdType="pmc">PMC9279511</ArticleId><ArticleId IdType="pubmed">35847514</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>